Association analysis of NAD(P)H:quinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan [1]

International Journal of Neuropsychopharmacology

Volumn 8, Issue 3, 2005, Pages 483-486

  Liou, Ying Jay ^a,b   Wang, Ying Chieh ^a,c   Lin, Chao Cheng ^a   Bai, Ya Mei ^a,b   Lai, I Ching ^a   Liao, Ding Lieh ^d   Chen, Jen Yeu ^a  

^a YULI VETERANS HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

^d Pali Psychiatric Hospital   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; PROLINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SERINE;

ADULT; AGED; ENZYME ANALYSIS; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NQO1 GENE; PRIORITY JOURNAL; SCHIZOPHRENIA; TAIWAN; TARDIVE DYSKINESIA;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CHI-SQUARE DISTRIBUTION; DNA MUTATIONAL ANALYSIS; DYSKINESIAS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, GENETIC; PROLINE; SCHIZOPHRENIA; SERINE; TAIWAN;

EID: 22344445737     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145705005262     Document Type: Letter

References (10)

1. Bai YM, Yu SC, Lin CC (2003). Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 64, 1342-1348.
2. Correll CU, Leucht S, Kane JM (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. American Journal of Psychiatry 161, 414-425.
3. Drukarch B, van Muiswinkel FL (2000). Drug treatment of Parkinson's disease. Time for phase II. Biochemical Pharmacology 59, 1023-1031. DOI: 10.1016/S0006-2952(99)00340-8.
4. Elkashef AM, Wyatt RJ (1999). Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophrenia Bulletin 25, 731-740.
5. Hori H, Ohmori O, Matsumoto C, Shinkai T, Nakamura J (2003). NAD(P)H:quinone oxidoreductase (NQO1) gene polymorphism and schizophrenia. Psychiatry Research 118, 235-239. DOI: 10.1016/S0165-1781(03)00095-7.
6. Lin P, Hsueh YM, Ko JL, Liang YF, Tsai KJ, Chen CY (2003). Analysis of NQO1, GSTP1, and MnSOD genetic polymorphisms on lung cancer risk in Taiwan. Lung Cancer 40, 123-129. DOI: 10.1016/S0169-5002(03)00027-8.
7. Lohr JB, Kuczenski R, Niculescu AB (2003). Oxidative mechanisms and tardive dyskinesia. CNS Drugs 17, 47-62.
8. Pae CU, Yu HS, Kim JJ, Lee CU, Lee SJ, Jun TY, Lee C, Paik IH (2004). Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. International Journal of Neuropsychopharmacology 7, 495-500. DOI: 10.1017/S1461145704004419.
9. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D (2000). NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chemico-Biological Interactions 129, 77-97. DOI: 10.1016/S0009-2797(00)00199-X.
10. Schooler NR, Kane JM (1982). Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 39, 486-487.